March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Anti-inflammatory Effect Of A Novel VAP-1 Inhibitor Molecule In Uveitis
Author Affiliations & Notes
  • Anna Enzsoly
    Dept of Ophthalmology,
    Semmelweis University, Budapest, Hungary
  • Romana Zelko
    University Pharmacy Department of Pharmacy Administration,
    Semmelweis University, Budapest, Hungary
  • Miklos Toth
    Research Institute of Sport Sciences,
    Semmelweis University, Budapest, Hungary
  • Peter Matyus
    Dept of Organic Chemistry,
    Semmelweis University, Budapest, Hungary
  • Janos Nemeth
    Dept of Ophthalmology,
    Semmelweis University, Budapest, Hungary
  • David A. Ammar
    Dept of Ophthalmology, University of Colorado, Denver, Colorado
  • J. M. Petrash
    Dept of Ophthalmology, University of Colorado, Denver, Colorado
  • Footnotes
    Commercial Relationships  Anna Enzsoly, None; Romana Zelko, None; Miklos Toth, None; Peter Matyus, None; Janos Nemeth, None; David A. Ammar, None; J. M. Petrash, None
  • Footnotes
    Support  TÁMOP-4.2.1/B-09/1/KMR-2010-0001; NIH Grant EY005856; DCER Fellowship from the ARVO Foundation for Eye Research.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3224. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anna Enzsoly, Romana Zelko, Miklos Toth, Peter Matyus, Janos Nemeth, David A. Ammar, J. M. Petrash; Anti-inflammatory Effect Of A Novel VAP-1 Inhibitor Molecule In Uveitis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3224.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The aim of this study was to evaluate the effects of VAP-1 inhibitors on a mouse model of uveitis.

Methods: : Uveitis was induced in mice (n=20) with a single intraperitoneal injection of lipopolysaccharide. The animals were randomly divided into different treatment groups. Group 1 as a control group received vehicle, group 2 and 3 were treated with different doses of a specific VAP-1 inhibitor LJP 1207 [N-(2-phenylallyl)hydrazine hydrochloride], group 4 was treated with our own VAP-1 inhibitor [3-(3,4-diphenyl-1,3-oxazol-2-yl)propanal oxime, SzV-1287]. 24 hours later, mice were sacrificed. Severity of the uveitis was assessed based on the number of inflammatory cells in the vitreous cavity and the anterior chamber, on sections passing through the optic nerve, stained with hematoxylin-eosin. ANOVA test was used for statistical analysis, and the differences between the groups were evaluated using Fisher post hoc test.

Results: : Histopathological images showed a marked inflammatory response in the vehicle-treated group (average cell number±SD: 40.15±8.525). Treatment with our novel VAP-1 inhibitor resulted a significant suppression of inflammation according to the vehicle-treated group (p<0.019) and to LJP 1207 treated group (p<0.03). However, there was no significant difference between the anti-inflammatory effects of high-dose LJP 1207 and the vehicle-treated group (p>0.6).

Conclusions: : In this uveitis model, our novel VAP-1 inhibitor showed a highly significant anti-inflammatory effect. We have also demonstrated that it was more effective than the reference VAP-1 inhibitor LJP 1207, therefore it may have therapeutic potentials for inflammatory eye diseases.

Keywords: uveitis-clinical/animal model 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.